Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Enanta Pharmaceuticals (NASDAQ: ENTA ) , a small-molecule drug developer targeted at infectious disease, soared as much as 20% after clinical partner AbbVie (NYSE: ABBV ) reported positive results from its second phase 3 trial of six (known as Sapphire-II) in treating experienced genotype 1 hepatitis-C patients.
So what: According to Enanta and AbbVie's press release, AbbVie's direct-acting antiviral combo, which consists of Enanta's ABT-450, as well as ABT-267 and ABT-333, demonstrated a sustained virologic response after 12 weeks of an incredible 96% in chronically infected genotype 1 patients who had been previously treated with and failed to respond to pegylated interferon and ribavirin. Also according to the release, nearly half of those patients were null responders under pegylated interferon and ribavirin treatment. The DAA combo was also well-tolerated with just 1% of the patient population dropping out due to adverse events.
Now what: These results are incredible -- that's all I have to say! Genotype 1 is by far the most common form of the disease, and this combo drug, in a matter of 12 weeks has practically eradicated it in nearly every patient! Furthermore, it did so without the use of interferon which can cause nasty flu-like side effects in patients. With Gilead Sciences (NASDAQ: GILD ) getting Sovaldi approved on Friday as an interferon-free treatment for genotype 2 & 3 hepatitis C (as well as in conjunction with interferon in type 1 and 4 genotypes), we're rapidly seeing the potential for improving hepatitis-C patients' quality of life go up. As for Enanta, the potential for this DAA combo's approval is going to be huge because, at the moment, the data would signify it could be a monster drug. Even following its near doubling over the past couple of weeks, I would suggest, if approved, that Enanta could have more upside.
The other amazing opportunity you won't want to miss
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.